medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2020, Number 4

<< Back Next >>

Rev Nefrol Dial Traspl 2020; 40 (4)

Antibody Levels of M Type Phospholipase A2 Receptor in Patients with Membranous Nephropaty and the Nephrotic Syndrome

Vilches A, Biaiñ ME, Laham G, Díaz C, Carrizo C, Iottti R

Language: Spanish
References: 21
Page: 283-294
PDF size: 468.28 Kb.


ABSTRACT

Introduction: Primary membranous nephropathy is one of the most frequent histological and immunohistochemical phenotypes in adult patients with nephrotic syndrome. With the identification of the M-type phospholipase A2 receptor (PLA2R), detection of serum anti-PLA2 has changed the diagnostic approach, the control of therapeutic efficacy and the evolution followup of this nephropathy. In most series, about 70% of MN treatment-naive patients test positive for this antibody. Objective: Our aim is to ascertain antibody level in MN patients and in nephrotic syndrome patients. Methods: In this retrospective observational study, 101 patients were evaluated (86 cases of MN diagnosed by renal biopsy and 15 with no pathologic diagnosis). They underwent the anti-PLA2R test. Demographic data, lab results (creatinine, albumin, proteinuria), renal histopathology and treatments administered were analyzed. We split MN patients diagnosed by renal biopsy into two groups according to anti- PLA2R results: Positive (those having values ≥ 20 U/mL) and Negative ([n=56] values ≤ 14 U/mL). Patients with equivocal results were not included. Results: From the total number of PMN patients diagnosed by renal biopsy, 29% (n=25) were positive for anti-PLA2R; 5.8% (n=5) had equivocal results, and 65.2% (n=56) were negative. Only 1 of the 15 patients suffering from nephrotic syndrome with no pathologic diagnosis was positive for anti- PLA2R. Anti-PLA2R testing results were positive for 47.7% of patients in a subgroup (n=35) that underwent the test no more than months after renal biopsy. No significant differences were found between the anti-PLA2R positive (n=25) and negative (n=56) groups regarding age, sex, albumin level, plasmatic creatinine and proteinuria. Conclusions: In our sample we obtained a low percentage of anti-PLA2R positivity compared to what was reported in the literature. Anti-PLA2R testing should be performed at the beginning of a nephrotic syndrome, prior to any treatment so as to determine the need of a renal biopsy, or with the result of a renal biopsy to determine if it is a primary or secondary form and evaluate the response to drugs or to “active surveillance”.


REFERENCES

  1. Ronco P, Debiec H. Pathophysiological advances inmembranous nephropathy: time for a shift in patient’scare. Lancet. 2015;385(9981):1983-92. doi: 10.1016/S0140-6736(15)60731-0.

  2. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, PowellDW, Cummins TD, et al. M-type phospholipase A2receptor as target antigen in idiopathic membranousnephropathy. N Engl J Med. 2009;361(1):11-21. doi:10.1056/NEJMoa0810457.

  3. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranousnephropathy. N Engl J Med. 2014;371(24):2277-87.doi: 10.1056/NEJMoa1409354.

  4. Sethi S, Debiec H, Madden B, Charlesworth MC,Morelle J, Gross LA, et al. Neural epidermal growthfactor-like 1 protein (NELL-1) associated membranousnephropathy. Kidney Int. 2020;97(1):163-74. doi:10.1016/j.kint.2019.09.014.

  5. Hihara K, Iyoda M, Tachibana S, Iseri K, Saito T,Yamamoto Y, et al. Anti-Phospholipase A2 receptor(PLA2R) antibody and glomerular PLA2R expressionin japanese patients with membranous nephropathy.PLoS One. 2016;11(6):e0158154. doi: 10.1371/journal.pone.0158154.

  6. Beck LH Jr, Salant DJ. Membranous nephropathy:from models to man. J Clin Invest. 2014;124(6):2307-14. doi: 10.1172/JCI72270.

  7. Cravedi P, Abbate M, Gagliardini E, Galbusera M,Buelli S, Sabadini E, et al. Membranous nephropathyassociated with IgG4-related disease. Am J Kidney Dis.2011;58(2):272-5. doi: 10.1053/j.ajkd.2011.05.002.

  8. Francis JM, Beck LH Jr, Salant DJ. Membranousnephropathy: a journey from bench to bedside. AmJ Kidney Dis. 2016;68(1):138-47. doi: 10.1053/j.ajkd.2016.01.030.

  9. Xie Q, Li Y, Xue J, Xiong Z, Wang L, Sun Z, et al.Renal phospholipase A2 receptor in hepatitis B virusassociatedmembranous nephropathy. Am J Nephrol.2015;41(4-5):345-53. doi: 10.1159/000431331.

  10. Stehlé T, Audard V, Ronco P, Debiec H.Phospholipase A2 receptor and sarcoidosis-associatedmembranous nephropathy. Nephrol Dial Transplant.2015;30(6):1047-50. doi: 10.1093/ndt/gfv080.

  11. Bobart SA, De Vriese AS, Pawar AS, Zand L, SethiS, Giesen C, et al. Noninvasive diagnosis of primarymembranous nephropathy using phospholipase A2receptor antibodies. Kidney Int. 2019;95(2):429-38.doi: 10.1016/j.kint.2018.10.021.

  12. Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R,Mathieson PW, et al. Antiphospholipase A2 receptorantibody titer and subclass in idiopathic membranousnephropathy. J Am Soc Nephrol. 2012;23(10):1735-43.doi: 10.1681/ASN.2012030242.

  13. Jiang Z, Cai M, Dong B, Yan Y, Yang Y, Wang M, et al.Clinicopathological features of atypical membranousnephropathy with unknown etiology in adult chinesepatients. Medicine (Baltimore). 2018;97(32):e11608.doi: 10.1097/MD.0000000000011608

  14. Díaz M, Agraz I, Soler MJ. Anti-phospholipaseA2 receptor antibody and spontaneous remissionin membranous nephropathy. Clin Kidney J.2019;12(1):33-5. doi: 10.1093/ckj/sfy079.

  15. Fervenza FC, Appel GB, Barbour SJ, RovinBH, Lafayette RA, Aslam N, et al. Rituximabor cyclosporine in the treatment of membranousnephropathy. N Engl J Med. 2019;381(1):36-46. doi:10.1056/NEJMoa181442.

  16. Dahan K, Debiec H, Plaisier E, Cachanado M,Rousseau A, Wakselman L, et al. Rituximab for severemembranous nephropathy: a 6-month trial withextended follow-up. J Am Soc Nephrol. 2017;28(1):348-58. doi: 10.1681/ASN.2016040449.

  17. Wu X, Liu L, Guo Y, Yang L. Clinical value of a serumanti-PLA2R antibody in the diagnosis and monitoringof primary membranous nephropathy in adults. IntJ Nephrol Renovasc Dis. 2018;11:241-7. doi: 10.2147/IJNRD.S176665.

  18. Ruggenenti P, Debiec H, Ruggiero B, Chianca A, PelléT, Gaspari F, et al. Anti-Phospholipase A2 receptorantibody titer predicts post-rituximab outcomeof membranous nephropathy. J Am Soc Nephrol.2015;26(10):2545-58. doi: 10.1681/ASN.2014070640.

  19. Beck LH Jr, Fervenza FC, Beck DM, BonegioRG, Malik FA, Erickson SB, et al. Rituximabinduceddepletion of anti-PLA2R autoantibodiespredicts response in membranous nephropathy. JAm Soc Nephrol. 2011;22(8):1543-50. doi: 10.1681/ASN.2010111125.

  20. Bomback AS. Management of membranousnephropathy in the PLA2R era. Clin J Am Soc Nephrol.2018;13(5):784-86. doi: 10.2215/CJN.12461117.

  21. García-Vives E, Solé C, Moliné T, Alvarez-RíosAM, Vidal M, Agraz I, et al. Antibodies to M-typephospholipase A2 receptor (PLA2R) in membranouslupus nephritis. Lupus. 2019;28(3):396-405. doi:10.1177/0961203319828521.




2020     |     www.medigraphic.com